Bioscience firm that's developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Tetra Bio Pharma
Funds will be used to advance the company’s work on QIXLEEF, a therapy to treat uncontrolled pain in advanced cancer patients that’s in the late-phase drug development stage.
An Ottawa bioscience company is turning to the markets for an injection of capital, announcing plans this week for a bought deal offering
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers.
Tetra Bio-Pharma (
Tetra Bio-Pharma raised a few extra million dollars this week, as the Orléans-based firm announced an expansion into the European medical cannabis market.
An Orleans-based cannabinoid drug company announced plans Thursday to raise $8 million in a bought deal offering.
With their expansion plans in high gear, two of the region’s marijuana firms are strengthening their executive teams with several high-profile appointments.
Armed with a new name and fresh funding, a local medical marijuana firm says it hopes to bring its pharmaceutical product to market in early 2018, a company executive says.